417 related articles for article (PubMed ID: 19637973)
41. Nanotechnology in ocular drug delivery.
Sahoo SK; Dilnawaz F; Krishnakumar S
Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
[TBL] [Abstract][Full Text] [Related]
42. Use of degradable and nondegradable nanomaterials for controlled release.
Wan WK; Yang L; Padavan DT
Nanomedicine (Lond); 2007 Aug; 2(4):483-509. PubMed ID: 17716133
[TBL] [Abstract][Full Text] [Related]
43. Nanotechnology Assisted Targeted Drug Delivery for Bone Disorders: Potentials and Clinical Perspectives.
Zhao X; Li L; Chen M; Xu Y; Zhang S; Chen W; Liang W
Curr Top Med Chem; 2020; 20(30):2801-2819. PubMed ID: 33076808
[TBL] [Abstract][Full Text] [Related]
44. Adaptations of nanoscale viruses and other protein cages for medical applications.
Lee LA; Wang Q
Nanomedicine; 2006 Sep; 2(3):137-49. PubMed ID: 17292136
[TBL] [Abstract][Full Text] [Related]
45. Designing proteins for bone targeting.
Gittens SA; Bansal G; Zernicke RF; Uludağ H
Adv Drug Deliv Rev; 2005 May; 57(7):1011-36. PubMed ID: 15876401
[TBL] [Abstract][Full Text] [Related]
46. Inhaled nanoparticles--a current review.
Yang W; Peters JI; Williams RO
Int J Pharm; 2008 May; 356(1-2):239-47. PubMed ID: 18358652
[TBL] [Abstract][Full Text] [Related]
47. Continuous nanostructures for the controlled release of drugs.
Venugopal J; Prabhakaran MP; Low S; Choon AT; Deepika G; Dev VR; Ramakrishna S
Curr Pharm Des; 2009; 15(15):1799-808. PubMed ID: 19442191
[TBL] [Abstract][Full Text] [Related]
48. Multifunctional nanoparticles--properties and prospects for their use in human medicine.
Sanvicens N; Marco MP
Trends Biotechnol; 2008 Aug; 26(8):425-33. PubMed ID: 18514941
[TBL] [Abstract][Full Text] [Related]
49. Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow.
Moghimi SM; Illum L; Davis SS
Crit Rev Ther Drug Carrier Syst; 1990; 7(3):187-209. PubMed ID: 2073686
[TBL] [Abstract][Full Text] [Related]
50. [Using nanotechnology and nanomaterials in ophthalmology].
Zhdanova OV; Chekman IS; Rykov SO
Lik Sprava; 2010; (5-6):21-30. PubMed ID: 21488365
[TBL] [Abstract][Full Text] [Related]
51. [Custom-made artificial bones fabricated by an inkjet printing technology].
Igawa K; Chung UI; Tei Y
Clin Calcium; 2008 Dec; 18(12):1737-43. PubMed ID: 19043187
[TBL] [Abstract][Full Text] [Related]
52. Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery.
Iqbal HMN; Rodriguez AMV; Khandia R; Munjal A; Dhama K
Recent Pat Inflamm Allergy Drug Discov; 2017; 10(2):86-93. PubMed ID: 27978790
[TBL] [Abstract][Full Text] [Related]
53. Broad overview of engineering of functional nanosystems for skin delivery.
Mota AH; Rijo P; Molpeceres J; Reis CP
Int J Pharm; 2017 Nov; 532(2):710-728. PubMed ID: 28764984
[TBL] [Abstract][Full Text] [Related]
54. Role of Nanoparticles in Drug Delivery and Regenerative Therapy for Bone Diseases.
Gera S; Sampathi S; Dodoala S
Curr Drug Deliv; 2017; 14(7):904-916. PubMed ID: 28034360
[TBL] [Abstract][Full Text] [Related]
55. Nanobiotechnology and bone regeneration: a mini-review.
Gusić N; Ivković A; VaFaye J; Vukasović A; Ivković J; Hudetz D; Janković S
Int Orthop; 2014 Sep; 38(9):1877-84. PubMed ID: 24962293
[TBL] [Abstract][Full Text] [Related]
56. A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs.
Huang WC; Hu SH; Liu KH; Chen SY; Liu DM
J Control Release; 2009 Nov; 139(3):221-8. PubMed ID: 19607866
[TBL] [Abstract][Full Text] [Related]
57. On the nature of biomaterials.
Williams DF
Biomaterials; 2009 Oct; 30(30):5897-909. PubMed ID: 19651435
[TBL] [Abstract][Full Text] [Related]
58. Immunological properties of engineered nanomaterials.
Dobrovolskaia MA; McNeil SE
Nat Nanotechnol; 2007 Aug; 2(8):469-78. PubMed ID: 18654343
[TBL] [Abstract][Full Text] [Related]
59. Nanostructured formulations and drug delivery systems.
Bunt CR
Pharm Dev Technol; 2018 Apr; 23(4):315. PubMed ID: 29514576
[No Abstract] [Full Text] [Related]
60. Advances in recognitive, conductive and responsive delivery systems.
Bayer CL; Peppas NA
J Control Release; 2008 Dec; 132(3):216-21. PubMed ID: 18652857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
